239 related articles for article (PubMed ID: 29685114)
1. Altruism, Scepticism, and collective decision-making in foreign-born U.S. residents in a tuberculosis vaccine trial.
Craig SR; Lahey T; Dixit A; Fordham von Reyn C
BMC Public Health; 2018 Apr; 18(1):535. PubMed ID: 29685114
[TBL] [Abstract][Full Text] [Related]
2. Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania.
Tarimo EA; Bakari M; Kakoko DC; Kohi TW; Mhalu F; Sandstrom E; Kulane A
BMC Public Health; 2016 Feb; 16():182. PubMed ID: 26911203
[TBL] [Abstract][Full Text] [Related]
3. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.
Masonou T; Hokey DA; Lahey T; Halliday A; Berrocal-Almanza LC; Wieland-Alter WF; Arbeit RD; Lalvani A; von Reyn CF
PLoS One; 2019; 14(5):e0217091. PubMed ID: 31120957
[TBL] [Abstract][Full Text] [Related]
5. [BCG vaccines for the prevention of tuberculosis in the world].
Hashimoto T
Kekkaku; 1997 Nov; 72(11):629-37. PubMed ID: 9423301
[TBL] [Abstract][Full Text] [Related]
6. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
7. Tuberculosis: vaccines in the pipeline.
Ly LH; McMurray DN
Expert Rev Vaccines; 2008 Jul; 7(5):635-50. PubMed ID: 18564018
[TBL] [Abstract][Full Text] [Related]
8. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs.
Park JN; White B; Bates A; Enriquez J; Liao L; Maher L
Drug Alcohol Depend; 2012 Jun; 123(1-3):35-40. PubMed ID: 22071117
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials.
Wilson L; Gracie L; Kidy F; Thomas GN; Nirantharakumar K; Greenfield S; Manaseki-Holland S; Ward DJ; Gooden TE
BMC Infect Dis; 2023 Feb; 23(1):120. PubMed ID: 36829123
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis vaccine development at a divide.
Kaufmann SH
Curr Opin Pulm Med; 2014 May; 20(3):294-300. PubMed ID: 24626237
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the development of new vaccines against tuberculosis. 100 years after the introduction of BCG].
Krysztopa-Grzybowska K; Lutyńska A
Postepy Hig Med Dosw (Online); 2014 Jun; 68():768-76. PubMed ID: 24934535
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.
Lahey T; Laddy D; Hill K; Schaeffer J; Hogg A; Keeble J; Dagg B; Ho MM; Arbeit RD; von Reyn CF
PLoS One; 2016; 11(12):e0168521. PubMed ID: 27997597
[TBL] [Abstract][Full Text] [Related]
15. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?
Martín C
Eur Respir J; 2005 Jul; 26(1):162-7. PubMed ID: 15994403
[TBL] [Abstract][Full Text] [Related]
16. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self.
McCann SK; Campbell MK; Entwistle VA
Trials; 2010 Mar; 11():31. PubMed ID: 20307273
[TBL] [Abstract][Full Text] [Related]
17. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
[TBL] [Abstract][Full Text] [Related]
18. Adolescent decision making about participation in a hypothetical HIV vaccine trial.
Alexander AB; Ott MA; Lally MA; Sniecinski K; Baker A; Zimet GD;
Vaccine; 2015 Mar; 33(11):1331-7. PubMed ID: 25645175
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis vaccine: A journey from BCG to present.
Fatima S; Kumari A; Das G; Dwivedi VP
Life Sci; 2020 Jul; 252():117594. PubMed ID: 32305522
[TBL] [Abstract][Full Text] [Related]
20. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
